PROState AI Cancer-Decision Support (PROSAIC-DS) – GSTT Trial

Deontics Cancer MDT solution was comprehensively evaluated in the prostate cancer pathway at Guys and St Thomas’s as part of an NIHR funded grant (Phase 3 Clinical Trial: NIHR and NHSx AI Award)

The PROSAIC-DS study retrospectively and prospectively evaluated the Deontics MDT streamlining application for prostate cancer cases referred to the Guy’s MDT.
Key Findings:

• Retrospective Analysis: In an analysis of 287 cases, the Deontics tool’s recommendations demonstrated a 92% concordance with the established gold standards.
• Prospective Analysis: Across 355 cases, Deontics successfully identified 33% of cases suitable to avoid full MDT discussion
• For the cases identified as suitable to avoid full MDT discussion, the tool provided recommendations with 98% concordance with the MDT decisions

 

Published results available in BJU at: https://pubmed.ncbi.nlm.nih.gov/40590412/